eFFECTOR Therapeutics Inc
F:LWK1

Watchlist Manager
eFFECTOR Therapeutics Inc Logo
eFFECTOR Therapeutics Inc
F:LWK1
Watchlist
Price: 9.1 EUR Market Closed
Market Cap: 1.1m EUR

eFFECTOR Therapeutics Inc
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

eFFECTOR Therapeutics Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
eFFECTOR Therapeutics Inc
F:LWK1
Accrued Liabilities
$4.1m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$3B
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
20%
No Stocks Found

eFFECTOR Therapeutics Inc
Glance View

Market Cap
1.1m EUR
Industry
Biotechnology

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California and currently employs 13 full-time employees. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The company uses selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The firm's lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an inhibitor of programed cell death protein 1 (PD-1) in a randomized Phase IIb clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase I/II clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

LWK1 Intrinsic Value
Not Available

See Also

What is eFFECTOR Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
4.1m USD

Based on the financial report for Dec 31, 2023, eFFECTOR Therapeutics Inc's Accrued Liabilities amounts to 4.1m USD.

What is eFFECTOR Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
33%

Over the last year, the Accrued Liabilities growth was 0%. The average annual Accrued Liabilities growth rates for eFFECTOR Therapeutics Inc have been 33% over the past three years .

Back to Top